|
Print version
Revised Short Paper Topics
The list of Short Paper Topics has been revised according to the
contributions submitted within the deadline of May 8. Submissions for poster presentations
are still accepted until June 15. Please choose an appropriate topic area when submitting
the paper, e.g. no. 3.5. Levels in feed and food.
Special Sessions are indicated by SP. For these sessions, several speakers
are being selected in advance. However, it is also possible to voluntarily submit relevant
short papers to these Special Sessions.
1.1 Formation, sources and source inventories
1.2 Thermal processes
1.3 Natural halogenated and chiral compounds (SP)
1.4 Contaminated sites: Cases, remediation, risk and policy (SP)
2.1 Sample preparation and analysis
2.3 Analysis - Biological methods
2.4 Analytical quality control and assurance
3.1 Ambient levels and trends 1 + 2
3.2 Occurrence in the Arctic environment (SP)
3.3 Levels in biota
3.4 Levels and effects in marine mammals (SP)
3.5 Levels in feed and food
3.6 Contaminated sediments: Mobility and bioavailability (SP)
4.1 Environmental transport and deposition
4.3 Biological, chemical and photolytical transformation
5.1 Dietary and non-dietary intake
5.2 Body burdens: Pattern, levels and trends
5.3 Occupational exposure
5.4 Dioxin exposure study in Midland, MI (SP)
6.1 Brominated compounds - Analytical methods
6.2 Brominated compounds - Chemistry and transformation
6.3 Brominated compounds - Sources and environmental levels
6.4 Brominated compounds - Human exposure
6.5 Brominated and fluorinated compounds - Toxic effects on wildlife and humans
7.1 Fluorinated compounds - Analytical Methods
7.3 Fluorinated compounds - Sources, environmental levels and transformation
7.4 Fluorinated compounds - Human exposure
8.1 Neurotoxicity and disorders (SP)
8.2 Bone and tooth development (SP)
8.3 Reproductive toxicity and disorders (SP)
8.4 Effects on the thyroid hormone system (SP)
8.6 Birth cohorts: What can be learned? (SP)
8.8 Biochemical and molecular mechanisms
9.2 Integrated risk assessment of BFRs as endocrine disrupters (SP)
9.3 Risk management and policy
9.4 Risk assessment
|
